I den centrale undersøgelse hos patienter med ovariecancer behandlet med en dosis på 50 mg/ m2, var myelosuppression generelt let til moderat, reversibel og var ikke forbundet med episoder af neutropenisk infektion eller sepsis.
In the pivotal trial in patients with ovarian cancer treated at a dose of 50 mg/ m2, myelosuppression was generally mild to moderate, reversible, and was not associated with episodes of neutropaenic infection or sepsis.